Rare Disease CROs in China
10 published
10 published CROs match Rare Disease in China.
Locations in this set include China, United States, Japan, United Kingdom, Australia, and India.
Capabilities that show up most often in this set: Phase II Clinical Trials, Phase III Clinical Trials, Phase IV / Post-Marketing, Clinical Operations, and Phase I Clinical Trials.
Matching companies
ClinilabsClinilabs is the leading CNS-focused CRO with 25+ years of expertise in neurotherapeutic clinical trials, offering Phase 1–4 trial management, early-phase development, clinical research units, and MedTech device expertise across psychiatry, neurology, substance use, and rare CNS disorders.
FortreaFortrea is a leading CRO advancing clinical trials through patient-focused clinical solutions that accelerate clinical development and drive trial success.
GemPharmatechGemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models.
ICON plcICON is a global clinical research organization providing full-service drug development and clinical trial solutions across early phase through post-marketing, including clinical operations, bioanalytical labs, cardiac safety, medical imaging, and regulatory affairs.
PPDPPD is a leading global contract research organization (CRO) and the clinical research business of Thermo Fisher Scientific.
PerceptiveLeading clinical research organization providing preclinical to late-phase imaging, randomization and trial supply management (RTSM), and eClinical services to the global biopharmaceutical industry.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
TRiCBIOTRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /indications/rare-disease/china.md